Last edition
News about "Gedeon Richter "
AbbVie and Gedeon Richter to Develop Novel Targets for Neuropsychiatric Conditions
This collaboration expands upon the success of nearly two decades of partnership on central nervous system (CNS) projects, including globally launched products such as cariprazine (VRAYLAR / REAGILA) and the discovery of investigational drug candidate ABBV-932 for the treatment of bipolar depression and generalized anxiety disorder.
Gedeon Richter | 25/10/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members